Netherlands Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

Netherlands Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Feb 2024 | No of Pages:  110 | No. Tables:  77 | No. Figures:  42

Market Definition

Netherlands Professional Acne Medication Market was valued at USD 34.25 million in 2023 and is predicted to reach USD 78.84 million by 2030, with a CAGR of 12.6% from 2024 to 2030. The professional acne medication market refers to specialized skincare formulations prescribed by dermatologists for targeted and effective acne treatment, addressing both inflammatory and non-inflammatory lesions while preventing scarring. These formulations offer advantages such as potent and tailored ingredients, often surpassing over-the-counter options.

Widely utilized in dermatology practices, professional acne medications cater to individuals with severe or persistent acne concerns, ensuring a higher level of efficacy and control. As the demand for advanced skincare rises, this market remains pivotal, providing personalized and medically guided approaches for achieving clearer and healthier skin.

Presence of Strong Healthcare and Skincare Practice Drives the Market

Netherlands's professional acne medication market thrives due to its exceptional healthcare standards and unwavering skincare emphasis. The country's world-renowned healthcare infrastructure ensures access to high-quality medical services, while the cultural spotlight on dermatological health encourages the pursuit of professional acne treatments. For instance, Netherlands's renowned Beiersdorf, with its NIVEA and Eucerin brands, continually innovates in skincare. This combination of excellent healthcare, cultural values, and the presence of pioneering skincare companies makes Netherlands a highly attractive hub for the expansion of professional acne medicine, fostering sustained market growth.

 

High Disposable Income Drives the Professional Acne Medication Market

Netherlands's professional acne medication market is driven by the nation's affluence on high disposable income. The country's robust economy ensures that a significant portion of its populace has the financial capacity to seek professional acne treatments, encompassing prescription medications, dermatological procedures, and premium skincare products. This affluence amplifies the market's growth potential as more individuals can afford advanced and comprehensive acne treatments. Consequently, the demand for professional acne medication in Netherlands is steadily increasing, making it a promising growth factor for the market.

 

High Healthcare Costs and Limited Insurance Coverage Hinders the Market

High healthcare costs and limited insurance coverage are significant restraints on the growth of the professional acne medication market in Netherlands. As a result, the professional acne medication market faces challenges in expanding its customer base and meeting the needs of those who may benefit from such treatments.

Advancement in Medical Technology Creates Lucrative Growth Opportunity for the Market

Innovative treatments present a substantial opportunity for future growth in the professional acne medication market in Netherlands. Continuous advancements in medical technology, such as laser therapy, microneedling, and advanced skincare products, offer more effective and less invasive solutions for acne management. The cutting-edge laser treatments can precisely target acne lesions, reducing scarring and promoting smoother skin. Innovative approaches like microneedling enhance the penetration of topical medications, increasing treatment efficiency. These technological innovations not only improve treatment outcomes but also enhance patient comfort and satisfaction. As patients seek more advanced and convenient solutions, the adoption of these innovative treatments is expected to drive significant growth in the professional acne medication market in Netherlands.

 

Competitive Landscape

The Netherlands professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

Netherlands Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 34.25 Million

Revenue Forecast in 2030

USD 78.84 Million

Growth Rate

CAGR of 12.6% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Presence of strong health and skincare practices.

High disposable income.

Companies Profiled

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET – EXECUTIVE SUMMARY

           2.1.      MARKET SNAPSHOT, 2023 - 2030, MILLION USD

3      PORTER’S FIVE FORCE MODEL ANALYSIS

           3.1      BARGAINING POWER OF SUPPLIERS

           3.2      BARGAINING POWER OF BUYERS

           3.3      DEGREE OF COMPETITION

           3.4      THREAT OF SUBSTITUTE

           3.5      THREAT OF NEW ENTRANTS

4      MARKET SHARE ANALYSIS

           4.1      MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2023

5      MARKET DYNAMICS

           5.1      GROWTH DRIVERS

                         5.1.1      DRIVER 1

                         5.1.2      DRIVER 2

                         5.1.3      DRIVER 3

                         5.1.4      DRIVER 4

           5.2      CHALLENGES

                         5.2.1      CHALLENGE 1

                         5.2.2      CHALLENGE 2

                         5.2.3      CHALLENGE 3

                         5.2.4      CHALLENGE 4

           5.3      OPPORTUNITIES

                         5.3.1      OPPORTUNITY 1

                         5.3.2      OPPORTUNITY 2

6       NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           6.1      OVERVIEW

           6.2      INFLAMMATORY ACNE MARKET

           6.3      NON-INFLAMMATORY ACNE MARKET

7       NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           7.1      OVERVIEW

           7.2      TOPICAL MEDICATIONS MARKET

           7.3      ORAL MEDICATIONS MARKET

8       NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           8.1      OVERVIEW

           8.2      RETINOIDS MARKET

           8.3      ANTIBIOTICS MARKET

           8.4      SALICYLIC ACID MARKET

           8.5      BENZOYL PEROXIDE MARKET

           8.6      OTHERS MARKET

9       NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           9.1      OVERVIEW

           9.2      MED SPA MARKET

           9.3      AESTHETICIAN MARKET

           9.4      DERMATOLOGIST MARKET

           9.5      OTHER PROFESSIONAL CHANNELS MARKET

10   COMPANY PROFILES

           10.1   ALMIRALL S.A.

                         10.1.1   COMPANY OVERVIEW

                         10.1.2   COMPANY SNAPSHOT

                         10.1.3   OPERATING BUSINESS SEGMENTS

                         10.1.4   PRODUCT PORTFOLIO

                         10.1.5   BUSINESS PERFORMANCE

                         10.1.6   BUSINESS SEGMENTS

                         10.1.7   GEOGRAPHIC SEGMENTS

                         10.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.1.9   PRIMARY MARKET COMPETITORS

           10.2   BAUSCH HEALTH COMPANIES, INC.

                         10.2.1   COMPANY OVERVIEW

                         10.2.2   COMPANY SNAPSHOT

                         10.2.3   OPERATING BUSINESS SEGMENTS

                         10.2.4   PRODUCT PORTFOLIO

                         10.2.5   BUSINESS PERFORMANCE

                         10.2.6   BUSINESS SEGMENTS

                         10.2.7   GEOGRAPHIC SEGMENTS

                         10.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.2.9   PRIMARY MARKET COMPETITORS

           10.3   GLAXOSMITHKLINE PLC (GSK)

                         10.3.1   COMPANY OVERVIEW

                         10.3.2   COMPANY SNAPSHOT

                         10.3.3   OPERATING BUSINESS SEGMENTS

                         10.3.4   PRODUCT PORTFOLIO

                         10.3.5   BUSINESS PERFORMANCE

                         10.3.6   BUSINESS SEGMENTS

                         10.3.7   GEOGRAPHIC SEGMENTS

                         10.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.3.9   PRIMARY MARKET COMPETITORS

           10.4   GALDERMA S.A.

                         10.4.1   COMPANY OVERVIEW

                         10.4.2   COMPANY SNAPSHOT

                         10.4.3   OPERATING BUSINESS SEGMENTS

                         10.4.4   PRODUCT PORTFOLIO

                         10.4.5   BUSINESS PERFORMANCE

                         10.4.6   BUSINESS SEGMENTS

                         10.4.7   GEOGRAPHIC SEGMENTS

                         10.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.4.9   PRIMARY MARKET COMPETITORS

           10.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         10.5.1   COMPANY OVERVIEW

                         10.5.2   COMPANY SNAPSHOT

                         10.5.3   OPERATING BUSINESS SEGMENTS

                         10.5.4   PRODUCT PORTFOLIO

                         10.5.5   BUSINESS PERFORMANCE

                         10.5.6   BUSINESS SEGMENTS

                         10.5.7   GEOGRAPHIC SEGMENTS

                         10.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.5.9   PRIMARY MARKET COMPETITORS

           10.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         10.6.1   COMPANY OVERVIEW

                         10.6.2   COMPANY SNAPSHOT

                         10.6.3   OPERATING BUSINESS SEGMENTS

                         10.6.4   PRODUCT PORTFOLIO

                         10.6.5   BUSINESS PERFORMANCE

                         10.6.6   BUSINESS SEGMENTS

                         10.6.7   GEOGRAPHIC SEGMENTS

                         10.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.6.9   PRIMARY MARKET COMPETITORS

           10.7   JOHNSON AND JOHNSON

                         10.7.1   COMPANY OVERVIEW

                         10.7.2   COMPANY SNAPSHOT

                         10.7.3   OPERATING BUSINESS SEGMENTS

                         10.7.4   PRODUCT PORTFOLIO

                         10.7.5   BUSINESS PERFORMANCE

                         10.7.6   BUSINESS SEGMENTS

                         10.7.7   GEOGRAPHIC SEGMENTS

                         10.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.7.9   PRIMARY MARKET COMPETITORS

           10.8   ELI LILLY AND COMPANY

                         10.8.1   COMPANY OVERVIEW

                         10.8.2   COMPANY SNAPSHOT

                         10.8.3   OPERATING BUSINESS SEGMENTS

                         10.8.4   PRODUCT PORTFOLIO

                         10.8.5   BUSINESS PERFORMANCE

                         10.8.6   BUSINESS SEGMENTS

                         10.8.7   GEOGRAPHIC SEGMENTS

                         10.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.8.9   PRIMARY MARKET COMPETITORS

           10.9   MYLAN N.V.

                         10.9.1   COMPANY OVERVIEW

                         10.9.2   COMPANY SNAPSHOT

                         10.9.3   OPERATING BUSINESS SEGMENTS

                         10.9.4   PRODUCT PORTFOLIO

                         10.9.5   BUSINESS PERFORMANCE

                         10.9.6   BUSINESS SEGMENTS

                         10.9.7   GEOGRAPHIC SEGMENTS

                         10.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.9.9   PRIMARY MARKET COMPETITORS

           10.10   DAIICHI SANKYO COMPANY, LTD

                         10.10.1   COMPANY OVERVIEW

                         10.10.2   COMPANY SNAPSHOT

                         10.10.3   OPERATING BUSINESS SEGMENTS

                         10.10.4   PRODUCT PORTFOLIO

                         10.10.5   BUSINESS PERFORMANCE

                         10.10.6   BUSINESS SEGMENTS

                         10.10.7   GEOGRAPHIC SEGMENTS

                         10.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         10.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. ALMIRALL S.A.: COMPANY SNAPSHOT

TABLE 19. ALMIRALL S.A.: OPERATING BUSINESS SEGMENTS

TABLE 20. ALMIRALL S.A.: PRODUCT PORTFOLIO

TABLE 21. ALMIRALL S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. ALMIRALL S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. ALMIRALL S.A.: KEY STRATERGY

TABLE 24. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 25. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 26. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 27. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 30. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 31. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 32. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 33. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 36. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 37. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 38. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 39. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. GALDERMA S.A.: KEY STRATERGY

TABLE 42. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 43. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 54. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 56. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 57. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 60. ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 61. ELI LILLY AND COMPANY: OPERATING BUSINESS SEGMENTS

TABLE 62. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 63. ELI LILLY AND COMPANY: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. ELI LILLY AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. ELI LILLY AND COMPANY: KEY STRATERGY

TABLE 66. MYLAN N.V.: COMPANY SNAPSHOT

TABLE 67. MYLAN N.V.: OPERATING BUSINESS SEGMENTS

TABLE 68. MYLAN N.V.: PRODUCT PORTFOLIO

TABLE 69. MYLAN N.V.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. MYLAN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. MYLAN N.V.: KEY STRATERGY

TABLE 72. DAIICHI SANKYO COMPANY, LTD: COMPANY SNAPSHOT

TABLE 73. DAIICHI SANKYO COMPANY, LTD: OPERATING BUSINESS SEGMENTS

TABLE 74. DAIICHI SANKYO COMPANY, LTD: PRODUCT PORTFOLIO

TABLE 75. DAIICHI SANKYO COMPANY, LTD: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. DAIICHI SANKYO COMPANY, LTD: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. DAIICHI SANKYO COMPANY, LTD: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. NETHERLANDS PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. ALMIRALL S.A.: NET SALES, (2021-2023)

FIGURE 24. ALMIRALL S.A.: PRIMARY MARKET COMPETITORS

FIGURE 25. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 26. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 27. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 28. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 29. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 30. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 31. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 32. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 34. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 35. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 36. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 37. ELI LILLY AND COMPANY: NET SALES, (2021-2023)

FIGURE 38. ELI LILLY AND COMPANY: PRIMARY MARKET COMPETITORS

FIGURE 39. MYLAN N.V.: NET SALES, (2021-2023)

FIGURE 40. MYLAN N.V.: PRIMARY MARKET COMPETITORS

FIGURE 41. DAIICHI SANKYO COMPANY, LTD: NET SALES, (2021-2023)

FIGURE 42. DAIICHI SANKYO COMPANY, LTD: PRIMARY MARKET COMPETITOR

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc.


Frequently Asked Questions
What will be the worth of the Netherlands Professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the Netherlands professional acne medication market business is expected to hit at USD 78.84 million by 2030.

What are the leading companies in the Netherlands professional acne medication market?

The Netherlands professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc, Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Eli Lilly and Company, Mylan N.V., Daiichi Sankyo Company, Ltd and others.

What are the market segmentations and scope of the study for the Netherlands professional acne medication industry?

The Netherlands professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in Netherlands?

The growth of the professional acne medication market in Netherlands is primarily driven by exceptional healthcare standards with unwavering skincare emphasis and a prosperous population.

What is restraining the growth of the Netherlands professional acne medication market?

The high healthcare costs and limited insurance coverage present a substantial restraint on the market's growth in Netherlands.